Table 3 Anticoagulant treatment in nephrotic patients
Intervention | Nephrotic syndrome episodes (N = 22a) | No bleeding events (N = 17) | Bleeding events (N = 5) |
|---|---|---|---|
Type of DOAC – n (%) | |||
Apixaban | 10 (45) | 7 (41) | 3 (60) |
Rivaroxaban | 12 (55) | 10 (59) | 2 (40) |
DOAC treatment – n (%) | |||
Primary prophylaxis | 20 (91) | 16 (94) | 4 (80) |
Treatment | 2 (9) | 1 (6) | 1 (20) |
Duration of DOAC (days, median (IQR)) | 103 (21–403) | 47 (21–378) | 204 (109–897) |
Primary prophylaxis | 72 (21–326) | 45 (18–326) | 157 (65–551) |
Secondary prophylaxis | 970 (478–1462) | - | - |
DOAC are stopped due to – n (%) | |||
Plasma-albumin > 20 g/L | 11 (50) | 7 (41) | 4 (80) |
eGFR < 15 mL/min/1.73m2 | 3 (14) | 3 (18) | 0 (0) |
Ongoing at end of study | 6 (27) | 5 (29) | 1 (20) |
Other | 2 (9) | 2 (12) | 0 (0) |